Sirtris Pharmaceuticals, Inc.

Contact

Site Map

Sirtris is focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, such as Type 2 Diabetes. Our research focus is on modulating the sirtuins, a recently discovered class of enzymes involved in the aging process.

Sirtris, a GSK company www.gsk.com

+ 12.09.08	Sirtris CEO Delivers Closing Keynote Address at MassBio Investors Forum
+ 12.04.08	Sirtris' Michelle Dipp Receives Tech Dealmaker of the Year Award in the Life Sciences Category
+ 12.01.08	Christoph Westphal, CEO of Sirtris, promoted to Senior Vice President, Centre of Excellence for External Drug Discovery, GSK
+ 11.26.08	Research from the Lab of Sirtris Co-Founder David Sinclair Uncovers Potential Universal Culprit of Aging; Study Published in the Journal Cell
+ 11.14.08	Sirtris Executive Michelle Dipp Honored with Stevie Award for Women in Business
+ 11.13.08	Nature Study Elucidates Mechanism of Calorie Restriction and Sirtuin Activation
+ 11.05.08	Research showing that Sirtris' SIRT1 activator NCE treats Diabetes in preclinical model published in Cell Metabolism

Find information regarding our clinical trials and areas of research. Learn more

+ 01.12.09

Sirtris to Present at 4:00 p.m. PT at JPMorgan Healthcare Conference in San Francisco

This winter, Sirtris is looking to expand our dynamic team. If you’re looking for a fast-paced career in a creative and rewarding environment click here.